SONIVIE
SoniVie is developing an advanced denervation solution to treat pulmonary hypertension.
SONIVIE
Industry:
Health Care Health Diagnostics Medical
Founded:
2015-01-01
Address:
Rosh Ha'ayin, HaMerkaz, Israel
Country:
Israel
Website Url:
http://www.sonivie.com
Total Employee:
1+
Status:
Active
Total Funding:
2.5 M USD
Similar Organizations
Dxcover
The Future of Cancer Diagnostics
MediQuo
Spain’s 24-hour, 7-day-a-week medical chat application.
Quantitative Radiology Solutions
Quantitative Radiology Solutions offers advanced body-wide quantification of medical images.
RightAir
RightAir is developing noninvasive ventilators for COPD patients.
Zebra Medical Vision
Zebra Medical Vision is a medical imaging and analytics platform.
Current Advisors List
Current Employees Featured
Investors List
Accelmed
Accelmed investment in Venture Round - SoniVie
Official Site Inspections
http://www.sonivie.com Semrush global rank: 5.9 M Semrush visits lastest month: 1.4 K
- Host name: box5552.bluehost.com
- IP address: 162.241.218.94
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "SoniVie"
About us - SoniVie
SoniVie's lead product, TIVUS, is an investigational intravascular treatment that can be performed as part of a routine right heart catheterization for patients suffering from pulmonary arterial hypertension (PAH)See details»
SoniVie Raises $60m in Round C Financing, and Appoints New …
SoniVie - Crunchbase Company Profile & Funding
SoniVie closed its last funding round on Jan 9, 2023 from a Series C round. Who are SoniVie 's competitors? Alternatives and possible competitors to SoniVie may include Zebra Medical …See details»
SoniVie Raises $60m in Round C Financing, and Appoints New …
Jan 9, 2023 SoniVie is a medical device company developing TIVUS™, the only ultra-sound denervation platform with active development programs in three therapeutic areas: pulmonary …See details»
SoniVie - Funding, Financials, Valuation & Investors - Crunchbase
SoniVie is funded by 6 investors. TechWald Holding S.p.A. and Supernova Invest are the most recent investors. Which investors participated in the most funding rounds?See details»
Andera Partners invests in SoniVie, a medtech company ... - EQS …
Jan 10, 2023 TEL AVIV, ISRAEL, AND PARIS, FRANCE, JANUARY 10, 2023 — SoniVie Ltd. (“SoniVie” or the “Company”), a medical device company developing a proprietary solution to …See details»
SoniVie announces advancements in its renal denervation program ...
Jul 24, 2024 SoniVie, which has developed a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUS™) to treat a variety of hypertensive disorders, presented on May …See details»
SoniVie receives IDE approval from FDA for its Pilot study to treat ...
TEL AVIV, Israel, June 20, 2022 /PRNewswire/ -- SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUS™) to treat a variety of …See details»
Team - SoniVie
SoniVie's lead product, TIVUS, is an investigational intravascular treatment that can be performed as part of a routine right heart catheterization for patients suffering from pulmonary arterial hypertension (PAH)See details»
SoniVie announces enrollment completion in the REDUCED-1 pilot …
Jan 31, 2024 SoniVie is a medical device company developing the TIVUS™ Ultrasonic Denervation System, the only platform denervation technology with active development …See details»
Andera Partners invests in SoniVie, a medtech company …
Jan 10, 2023 SoniVie Ltd. (“SoniVie” or the “Company”), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million …See details»
SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W.
Nov 17, 2024 SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. …See details»
SoniVie Receives FDA Breakthrough Device Designation for the …
Dec 9, 2020 \\- SoniVie Acquires New Intellectual Property and Other Assets from Cardiosonic Moving TIVUS into New Therapeutic Areas Beyond Pulmonary Hypertension -TEL AVIV, …See details»
SoniVie receives IDE approval from FDA for its Pilot study to treat ...
Jun 20, 2022 SoniVie is a medical device company developing the TIVUS™, the only Ultra-Sound Denervation platform with active development programs in three therapeutic areas: …See details»
SoniVie Gets FDA OK for Renal Artery Denervation Study
Jun 20, 2022 SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUS) to treat a variety of hypertensive disorders, announced …See details»
SoniVie Raises $60m in Round C Financing, and Appoints New …
Jan 9, 2023 SoniVie is a medical device company developing TIVUS™, the only ultra-sound denervation platform with active development programs in three therapeutic areas: pulmonary …See details»
SoniVie Gains IDE Approval for THRIVE Pivotal ... - Endovascular …
Jul 24, 2024 SoniVie, which is based in Rehovot, Israel, and Minneapolis, Minnesota, advised that it has active development programs for Tivus in three therapeutic areas: renal artery …See details»
SoniVie Receives IDE Approval for its Pivotal Study for the TIVUS ...
Oct 13, 2020 SoniVie presented positive 12-month safety and efficacy data from the earlier TROPHY1 (TReatment Of Pulmonary HYpertension 1) study (NCT02835950 and …See details»
News - SoniVie
Jul 13, 2022 SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE approval, initiating the global THRIVE study in US, Europe and Israel SoniVie, which has …See details»